Search Result

Results for "

lysophosphatidic acid (LPA) receptor

" in MedChemExpress (MCE) Product Catalog:

標的別:	Akt (2) Apoptosis (2) Biochemical Assay Reagents (2) Cyclophilin (1) Drug Isomer (1) Endogenous Metabolite (1) Interleukin Related (2) LPL Receptor (31) MDM-2/p53 (1) Mitosis (2) p38 MAPK (2) PPAR (1) Reactive Oxygen Species (ROS) (1) Reference Standards (4)
研究分野別:	Cancer (8) Cardiovascular Disease (5) Endocrinology (2) Infection (2) Inflammation/Immunology (9) Metabolic Disease (6) Neurological Disease (11)
クリックケミストリー:	Alkynes (1)
Oligonucleotides:	Phospholipids (2)

阻害剤およびアゴニスト

生化学アッセイ試薬

天然物

抗体

クリックケミストリー

オリゴヌクレオチド

製品番号	製品名	Target	研究分野	構造式

HY-107614

1-Oleoyl lysophosphatidic acid sodium 3 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium	LPL Receptor Mitosis	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) sodium, a potent bioactive phospholipid, is a **LPA receptor** activator. 1-Oleoyl lysophosphatidic acid sodium can promote mitosis by inducing DNA synthesis. 1-Oleoyl lysophosphatidic acid sodium is also involved in normal and pathological emotional responses, including anxiety and depression .

HY-139853

BMS-986278 1 Publications Verification Admilparant	LPL Receptor	Others
BMS-986278 is a potent and orally active **lysophosphatidic acid receptor 1 (LPA1) antagonist, with K_b*s of 6.9 nM and 4.0 nM for human and mouse LPA*1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases .

HY-137862

1-Oleoyl lysophosphatidic acid 3 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate; 1-Oleoyl-LPA	LPL Receptor	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) is an abundant lysophosphatidic acid (LPA) species with high biological activity due to its strong affinity for the **LPA receptors*. 1-Oleoyl lysophosphatidic* acid is commonly used in most laboratories as a reagent for LPA receptor activation . 1-Oleoyl lysophosphatidic acid increases SRE-driven β-galactosidase activity .

HY-100619

BMS-986020 Maximum Cited Publications 9 Publications Verification AM152	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) is a high-affinity and selective **lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 inhibits bile acid and phospholipid transporters with IC₅₀**s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-114379

AS2717638 2 Publications Verification	LPL Receptor	Neurological Disease Inflammation/Immunology
AS2717638 is a highly selective, brain-penetrant and orally active **lysophosphatidic acid receptor 5 (LPA5) antagonist with an IC₅₀** value of 38 nM. AS2717638 is highly selective and shows no significant antagonistic activity against other LPA receptors (LPA1, LPA2, and LPA3). AS2717638 can be used in the research of pain and neuroinflammation-related diseases .

HY-100882

ONO-7300243	LPL Receptor	Cardiovascular Disease
ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC₅₀ of 0.16 μM.

HY-18076

LPA1 receptor antagonist 1	LPL Receptor	Infection Inflammation/Immunology
LPA1 receptor antagonist 1 is a highly selective Lysophosphatidic Acid receptor-1 *(LPA1)* antagonist with an IC₅₀ of 25 nM.

HY-150204

ONO-0740556	LPL Receptor	Others
ONO-0740556 is a potent Gi-coupled human lysophosphatidic acid receptor 1 (LPA1) agonist with an EC₅₀ value of 0.26 nM .

HY-157693

C18:1 Cyclic LPA	Endogenous Metabolite	Cancer
C18:1 Cyclic LPA is a naturally occurring analog of the growth factor-like phospholipid mediator, lysophosphatidic acid (LPA), characterized by the formation of a 5-membered ring between its sn-2 hydroxy group and the sn-3 phosphate. This unique structure allows C18:1 Cyclic LPA to influence a variety of cellular functions, such as inhibiting cell cycle progression, promoting the formation of stress fibers, curtailing tumor cell invasiveness and metastasis, and modulating the differentiation and survival of neuronal cells. Notably, many of these cellular effects elicited by C18:1 Cyclic LPA appear to counter those induced by LPA, despite the activation of seemingly similar receptor populations.

HY-120967

(2S)-OMPT triethylamine, in ethanol:chloroform (1:1), 98%	p38 MAPK Akt Interleukin Related	Cancer
(2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98%, Lysophosphatidic acid analogue, is a *LPA3* G-protein-coupled receptor agonist. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% can be used for the research of ovarian cancer .

HY-100619A

BMS-986020 sodium Maximum Cited Publications 9 Publications Verification AM152 sodium	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-15706

H2L 5765834 1 Publications Verification	LPL Receptor	Cardiovascular Disease
H2L 5765834 is an antagonist of **lysophosphatidic acid receptors LPA₁, LPA₃, and LPA₅, with IC₅₀**s of 94, 752, and 463 nM respectively .

HY-128127

NAEPA	LPL Receptor	Others
NAEPA, a phosphate-mimetic derivative, is a lysophosphatidic acid (LPA) receptor agonist .

HY-137862A

(Rac)-1-Oleoyl lysophosphatidic acid (Rac)-1-Oleoyl-sn-glycero-3-phosphate; (Rac)-1-Oleoyl-LPA	LPL Receptor Drug Isomer	Neurological Disease
(Rac)-1-Oleoyl lysophosphatidic acid is an isomer of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid that can activate the *LPA* receptors .

HY-114380

Radioprotectin-1	LPL Receptor	Others
Radioprotectin-1 is a potent and specific nonlipid agonist of **lysophosphatidic acid receptor 2 (LPA₂), with an EC₅₀** value of 25 nM for murine LPA₂ subtype .

HY-117444

ONO-9780307	LPL Receptor	Cancer
ONO-9780307 is a specific synthetic *LPA1* (lysophosphatidic acid receptor 1) antagonist with an IC₅₀ value of 2.7 nM .

HY-120967A

(2S)-OMPT	p38 MAPK Akt Interleukin Related	Cancer
(2S)-OMPT, Lysophosphatidic acid analogue, is a *LPA3* G-protein-coupled receptor agonist. (2S)-OMPT selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT can be used for the research of ovarian cancer .

HY-117779

DBIBB 2 Publications Verification	Apoptosis	Endocrinology
DBIBB is a specific nonlipid agonist of the type 2 G protein coupled receptor for lysophosphatidic acid (LPA2). DBIBB mitigates the gastrointestinal radiation syndrome, increases intestinal crypt survival and enterocyte proliferation, and reduces apoptosis. DBIBB represents a agent candidate capable of mitigating acute radiation syndrome caused by high-dose γ-radiation to the hematopoietic and gastrointestinal system .

HY-115450

ONO-0300302	LPL Receptor	Endocrinology Cancer
ONO-0300302 is an orally active and potent *LPA1* (lysophosphatidic acid receptor 1) antagonist, with an IC₅₀ of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with K_d of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research .

HY-120478

ASP6432	LPL Receptor	Infection
ASP6432 is a potent and selective type 1 lysophosphatidic acid receptor (LPA1) antagonist with IC₅₀s of 11 nM and 30 nM for human LPA1 and rat LPA1, respectively .

HY-W127502

1-Hexadecyl lysophosphatidic acid 1-Hexadecyl LPA; 1-Palmityl LPA; LPA O-16:0	Biochemical Assay Reagents	Others
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.

HY-167862A

UCM-05194 ammonium	LPL Receptor	Neurological Disease
UCM-05194 (ammonium) is a lysophosphatidic acid receptor 1 (LPA1) agonist. UCM-05194 (ammonium) induces calcium mobilization in LPA1-expressing RH7777 cells (EC₅₀ = 0.24 µM). UCM-05194 (ammonium) induces neurite retraction and migration in LPA1-overexpressing B103 rat neuroblastoma cells. UCM-05194 (ammonium) attenuates acetic acid-induced writhing and hind paw mechanical hypersensitivity in mice .

HY-151391

LPA5 antagonist 1	Biochemical Assay Reagents	Neurological Disease
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high blood-brain-barrier permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-124072

HL001	Cyclophilin LPL Receptor MDM-2/p53 Apoptosis Reactive Oxygen Species (ROS)	Cancer
HL001 is an orally active small molecule inhibitor of Cyclophilin A (CypA) and a receptor antagonist of Lysophosphatidic acid 1 (LPA1). HL001 induces cell cycle arrest and apoptosis of tumor cells by p53. HL001 stabilizes p53 by down-regulating G3BP1, inducing reactive oxygen species and DNA damage. HL001 disrupts the interaction between MDM2 and p53-72R in a CypA dependent manner. HL001 has antitumor activity. HL001 can also be used to study pulmonary fibrosis .

HY-N15794

AzoLPA ammonium	LPL Receptor	Neurological Disease
AzoLPA ammonium is a photoswitchable lipid that activates the **Lysophosphatidic acid 1-5 (LPA1-5) receptors**’ signaling .

HY-W040176

N-PTyrosine PA ammonium N-Palmitoyl-tyrosine phosphoric acid ammonium	LPL Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
N-PTyrosine PA (N-Palmitoyl-tyrosine phosphoric acid) ammonium is a **lysophosphatidic acid (LPA) receptor modulator, which exhibits weak inhibitory activity against LPA1 and partial agonist properties towards LPA5*. N-PTyrosine PA ammonium inhibits the activation of LPA* receptors and downstream responses by competing with agonists for binding sites. N-PTyrosine PA ammonium can induce morphological changes and aggregation, and also inhibit LPA-induced morphological changes through receptor desensitization caused by pre-incubation. N-PTyrosine PA ammonium can be used in the research of related diseases such as atherosclerosis and acute ischemic syndromes (e.g., unstable angina, myocardial infarction, stroke) .

HY-160173

LPA receptor antagonist-1	LPL Receptor	Others
LPA receptor antagonist-1 (example 52) is an antagonist of lysophosphatidic acid (LPA) receptor. LPA receptor antagonist-1 can be used for kinds of studies .

HY-171906A

1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA sodium 1-Arachidonoyl-sn-glycerol 3-phosphate sodium; 1-Arachidonoyl LPA sodium; LPA (20:4) sodium	LPL Receptor	Cancer
1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) (1-Arachidonoyl-sn-glycerol 3-phosphate (sodium)) is a phospholipid with arachifonic acid at the sn-1 position. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) binds to the *LPA₂/EDG4* receptor (EC₅₀ of 10 nM). 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) can be found in rat brain as 37% of the arachidoinic acid-containing lysophosphatidic acid species. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) is the precursor to 1-arachidonoyl glycerol. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) can prevent TNF-α and IL-6 secretion in wild type LPS-stimulated dendritic cells. 1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA (sodium) reduces differentiation of HT-29 colon carcinoma cells into goblet cells when sodium butyrate is present .

HY-175084

1-Hexadecyl lysophosphatidic acid sodium 1-Hexadecyl LPA sodium; 1-Palmityl LPA sodium; LPA O-16:0 sodium	LPL Receptor	Metabolic Disease
1-Hexadecyl lysophosphatidic acid (1-Hexadecyl LPA) sodium, an ether analog of lysophosphatidic acid (LPA), is a **LPA receptor** activator .

HY-160616

LPA5 antagonist 3	LPL Receptor	Cardiovascular Disease Neurological Disease
LPA5 antagonist 3 (Example 74) is a lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC₅₀ of 170 nM. LPA5 antagonist 3 can be used for the research of pain disorders and atherosclerosis .

HY-151392

LPA5 antagonist 2	LPL Receptor	Neurological Disease Inflammation/Immunology
LPA5 antagonist 2 (compound 65) is a high aqueous solubility *LPA5* (lysophosphatidic acid receptor 5) antagonist. LPA5 antagonist 2 significantly attenuates nociceptive hypersensitivity and it can be used for the research of inflammatory and neuropathic pains .

HY-W923661

1-Octadecyl lysophosphatidic acid PA(O-18:0/0:0); 1-Oleyl LPA; 1-Octadecyl LPA	LPL Receptor	Others
1-Octadecyl lysophosphatidic acid (compound 10) is a GPR92 receptor (LPA5) activator with potential flavoring effects .

HY-160823

2ccPA sodium 2ccPA18:1 sodium	LPL Receptor	Inflammation/Immunology Cancer
2ccPA sodium is a **lysophosphatidic acid (LPA) receptor** agonist. 2ccPA sodium modulates processes such as cell proliferation, migration, and apoptosis by activating LPA receptors and inhibiting autotaxin (ATX) enzyme activity. 2ccPA sodium is promising for research of cancers, inflammation, and fibrosis .

HY-160003

PPARγ agonist 9	PPAR	Metabolic Disease
PPARγ agonist 9 is an agonist of PPARγ. PPARγ agonist 9 is the analogue of lysophosphatidic acid with an EC₅₀ more than 10 μM for LPA₃ receptor .

HY-107614R

1-Oleoyl lysophosphatidic acid sodium (Standard) 1-Oleoyl-sn-glycero-3-phosphate sodium (Standard); 1-Oleoyl-LPA sodium (Standard)	LPL Receptor Mitosis Reference Standards	Neurological Disease
1-Oleoyl lysophosphatidic acid sodium (Standard) is the analytical standard of 1-Oleoyl lysophosphatidic acid (sodium) (HY-107614). This product is intended for research and analytical applications. 1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) sodium, a potent bioactive phospholipid, is a LPA receptor activator. 1-Oleoyl lysophosphatidic acid sodium can promote mitosis by inducing DNA synthesis. 1-Oleoyl lysophosphatidic acid sodium is also involved in normal and pathological emotional responses, including anxiety and depression .

HY-100882R

ONO-7300243 (Standard)	LPL Receptor Reference Standards	Cardiovascular Disease
ONO-7300243 (Standard) is the analytical standard of ONO-7300243 (HY-100882). This product is intended for research and analytical applications. ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC50 of 0.16 μM.

HY-100619AR

BMS-986020 sodium (Standard) AM152 sodium (Standard)	LPL Receptor Reference Standards	Metabolic Disease Inflammation/Immunology
BMS-986020 (sodium) (Standard) is the analytical standard of BMS-986020 (sodium) (HY-100619A). This product is intended for research and analytical applications. BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-100619R

BMS-986020 (Standard) AM152 (Standard)	LPL Receptor Reference Standards	Metabolic Disease Inflammation/Immunology
BMS-986020 (Standard) is the analytical standard of BMS-986020 (HY-100619). This product is intended for research and analytical applications. BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist . BMS-986020 inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively . BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

製品番号	製品名	Type

HY-120967

(2S)-OMPT triethylamine, in ethanol:chloroform (1:1), 98%	生化学アッセイ試薬
(2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98%, Lysophosphatidic acid analogue, is a *LPA3* G-protein-coupled receptor agonist. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% can be used for the research of ovarian cancer .

(2S)-OMPT triethylamine, in ethanol:chloroform (1:1), 98%

生化学アッセイ試薬

(2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98%, Lysophosphatidic acid analogue, is a LPA3 G-protein-coupled receptor agonist. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% can be used for the research of ovarian cancer .

HY-W127502

1-Hexadecyl lysophosphatidic acid 1-Hexadecyl LPA; 1-Palmityl LPA; LPA O-16:0	生化学アッセイ試薬
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.

製品番号	製品名	Category	Target	構造式

HY-N15794

AzoLPA ammonium	Lipid	LPL Receptor
AzoLPA ammonium is a photoswitchable lipid that activates the **Lysophosphatidic acid 1-5 (LPA1-5) receptors**’ signaling .

製品番号	Compare	製品名	Application	Reactivity	Image

HY-P83630

	EDG2 Antibody (YA3375) lysophosphatidic acid receptor 1; LPA receptor 1; LPA-1; lysophosphatidic acid receptor Edg-2; LPAR1; EDG2; LPA1	WB, IHC-P, ICC/IF, FC, IP	Human
	EDG2 Antibody (YA3375) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to EDG2.

Compare Products


Products	在庫あり - + カートに追加
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 在庫あり - + カートに追加お問い合わせ

製品番号	製品名		Classification

HY-151391

LPA5 antagonist 1		Alkynes
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high blood-brain-barrier permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

製品番号	製品名		Classification

HY-157693

C18:1 Cyclic LPA		Phospholipids
C18:1 Cyclic LPA is a naturally occurring analog of the growth factor-like phospholipid mediator, lysophosphatidic acid (LPA), characterized by the formation of a 5-membered ring between its sn-2 hydroxy group and the sn-3 phosphate. This unique structure allows C18:1 Cyclic LPA to influence a variety of cellular functions, such as inhibiting cell cycle progression, promoting the formation of stress fibers, curtailing tumor cell invasiveness and metastasis, and modulating the differentiation and survival of neuronal cells. Notably, many of these cellular effects elicited by C18:1 Cyclic LPA appear to counter those induced by LPA, despite the activation of seemingly similar receptor populations.

HY-120967A

(2S)-OMPT		Phospholipids
(2S)-OMPT, Lysophosphatidic acid analogue, is a *LPA3* G-protein-coupled receptor agonist. (2S)-OMPT selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT can be used for the research of ovarian cancer .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: